"We are very honored to be named as a Business Leader of the Scientific American 50," stated Victoria Hale, Ph.D., founder and CEO of OneWorld Health. "Through the unique business model of a nonprofit pharmaceutical company, we are able to target diseases of the poorest people in the world, where the development of new medicines is clearly not profitable. By creating collaborative partnerships among industry, academia, foundations, and the nonprofit sectors, we are addressing some of the world's most devastating diseases. As a result, we can develop new medicines and save lives of people most in need."
The 2004 Scientific American 50 will appear in Scientific American's December issue, available at newsstands on Nov. 23. Editor-In-Chief John Rennie described his magazine's commitment saying, "Scientific American believes strongly that the best hope for a safer, healthier, more prosperous world rests in the enlightened use of technology. The Scientific American 50 is our annual opportunity to salute the people and organizations making that possible through their outstanding efforts as leaders of research, industry and policymaking."
Proving the viability of OneWorld Health's business model, Dr. Hale announced today preliminary positive results of a Phase III clinical trial in India for a low-cost drug to cure a deadly parasitic disease, visceral leishmaniasis (VL) during a scientific session at the 53rd
Contact: Joanne Hasegawa
Institute for OneWorld Health